{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:56:14Z","timestamp":1793404574257,"version":"4.5.0"},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,12,15]]},"DOI":"10.2169\/internalmedicine.7425-21","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T22:08:01Z","timestamp":1624054081000},"page":"3941-3945","source":"Crossref","is-referenced-by-count":5,"title":["Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma"],"prefix":"10.2169","volume":"60","author":[{"given":"Keita","family":"Kawakado","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamoto","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375: 1823-1833, 2016.","DOI":"10.1056\/NEJMoa1606774"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378: 2078-2092, 2018.","DOI":"10.1056\/NEJMoa1801005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a ramdomised, controlled, phase 2 trial. Lancet Oncol 16: 908-918, 2015.","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kartal \u00d6, Ata\u015f E. Bilateral optic neuritis secondary to nivolumab therapy: a case report. Medicina (Kaunas) 54: 82, 2018.","DOI":"10.3390\/medicina54050082"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Makri OE, Dimitrakopoulos FI, Tsapardoni F, et al. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. Int J Neurosci 1-6, 2020.","DOI":"10.1080\/00207454.2020.1831489"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mori S, Kurimoto T, Ueda K, et al. Optic neuritis possibly induced by anti-PD-L1 antibody treatment in a patient with non-small cell lung carcinoma. Case Rep Ophthalmol 9: 348-356, 2018.","DOI":"10.1159\/000491075"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4: 66, 2016.","DOI":"10.1186\/s40425-016-0170-9"},{"key":"8","unstructured":"8. Senties-Madrid H, Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Isr Med Assoc J 3: 94-103, 2001."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Prze\u017adziecka-Do\u0142yk J, Brzecka A, Ejma M, et al. Ocular paraneoplastic syndromes. Biomedicines 8: 490, 2020.","DOI":"10.3390\/biomedicines8110490"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Dumoulin DW, Visser S, Cornelissen R, et al. Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol 15: 1472-1483, 2020.","DOI":"10.1016\/j.jtho.2020.04.021"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_7425-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T03:19:07Z","timestamp":1639797547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_7425-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":10,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7425-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"7425-21"}}